The polymer Carragelose® is a unique broadly active virus-blocking compound for treating respiratory diseases. It has been approved for marketing in the EU, parts of Asia and Australia as part of nasal sprays, throat sprays and lozenges. Carragelose® is a sulfated polymer from red seaweed also widely used in the food industry and has GRAS status (FDA). The compound has a broad spectrum of virus-blocking properties and is protected by a strong patent family.
New in vitro data show the virus-neutralising effect of Carragelose® on SARS-CoV-2
Mode of Action
Like a burr to textiles, cold viruses bind to the surfaces of the upper respiratory tract. Then the infection starts. It is time to interfere!
Sprayed into the nose, Carragelose® creates a protective layer in the nasal cavity that helps to reduce the spreading and proliferation of the common cold virus.
The clotted viruses leave the body via the natural route – the cold might not even come, stay shorter or leave faster. No virus – no cold – naturally achieved.
Safety and Efficacy
The safety and virus-blocking effectiveness of Carragelose® have been established in several clinical and non-clinical trials. Three double-blind, placebo-controlled clinical trials confirmed the virus-blocking effectiveness, a significant reduction of the duration of the disease, a significant reduction of viral load and a reduction of relapses.